Shuyan Du

1.5k total citations
28 papers, 640 citations indexed

About

Shuyan Du is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Shuyan Du has authored 28 papers receiving a total of 640 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 9 papers in Radiology, Nuclear Medicine and Imaging and 8 papers in Oncology. Recurrent topics in Shuyan Du's work include Liver Disease Diagnosis and Treatment (7 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Shuyan Du is often cited by papers focused on Liver Disease Diagnosis and Treatment (7 papers), Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (6 papers) and Lung Cancer Treatments and Mutations (5 papers). Shuyan Du collaborates with scholars based in United States, Denmark and Sweden. Shuyan Du's co-authors include Wendy Hayes, Edgar D. Charles, Zachary Goodman, Diane E. Shevell, Giridhar Tirucherai, M.A. Karsdal, Arun J. Sanyal, Rohit Loomba, Eric Lawitz and Lin Lü and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Hepatology.

In The Last Decade

Shuyan Du

28 papers receiving 629 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Shuyan Du United States	12	224	168	167	154	90	28	640
Wei Qiang Leow Singapore	13	248 1.1×	86 0.5×	133 0.8×	69 0.4×	213 2.4×	47	717
Yacine Hajji France	4	217 1.0×	134 0.8×	157 0.9×	65 0.4×	319 3.5×	4	606
Ji Hae Nahm South Korea	16	149 0.7×	172 1.0×	196 1.2×	78 0.5×	236 2.6×	52	785
Melissa M. Johnson United States	15	104 0.5×	103 0.6×	344 2.1×	77 0.5×	129 1.4×	36	756
Nicolas Poté France	16	284 1.3×	148 0.9×	184 1.1×	73 0.5×	342 3.8×	45	922
Kiat‐Hon Lim Singapore	12	143 0.6×	43 0.3×	111 0.7×	93 0.6×	92 1.0×	16	614
Sang Soo Kim South Korea	18	127 0.6×	283 1.7×	288 1.7×	52 0.3×	212 2.4×	45	845
Ye Jin Ha South Korea	13	320 1.4×	70 0.4×	160 1.0×	28 0.2×	184 2.0×	27	615
Hyeyoon Chang South Korea	13	83 0.4×	134 0.8×	155 0.9×	75 0.5×	30 0.3×	28	578

Countries citing papers authored by Shuyan Du

Since Specialization

Citations

This map shows the geographic impact of Shuyan Du's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shuyan Du with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shuyan Du more than expected).

Fields of papers citing papers by Shuyan Du

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shuyan Du. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shuyan Du. The network helps show where Shuyan Du may publish in the future.

Co-authorship network of co-authors of Shuyan Du

This figure shows the co-authorship network connecting the top 25 collaborators of Shuyan Du. A scholar is included among the top collaborators of Shuyan Du based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shuyan Du. Shuyan Du is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Brown, Elizabeth A., Anne Minnich, Arun J. Sanyal, et al.. (2023). Effect of pegbelfermin on NASH and fibrosis-related biomarkers and correlation with histological response in the FALCON 1 trial. JHEP Reports. 5(4). 100661–100661. 29 indexed citations

Loomba, Rohit, Arun J. Sanyal, Atsushi Nakajima, et al.. (2023). Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Stage 3 Fibrosis (FALCON 1): A Randomized Phase 2b Study. Clinical Gastroenterology and Hepatology. 22(1). 102–112.e9. 59 indexed citations

Abdelmalek, Manal F., Arun J. Sanyal, Atsushi Nakajima, et al.. (2023). Pegbelfermin in Patients With Nonalcoholic Steatohepatitis and Compensated Cirrhosis (FALCON 2): A Randomized Phase 2b Study. Clinical Gastroenterology and Hepatology. 22(1). 113–123.e9. 65 indexed citations

Donnelly, David J., Yunhui Zhang, Paul M. Scola, et al.. (2023). Development, Characterization, and Radiation Dosimetry Studies of 18F-BMS-986229, a 18F-Labeled PD-L1 Macrocyclic Peptide PET Tracer. Molecular Imaging and Biology. 26(2). 301–309. 3 indexed citations

Conaghan, Philip G., Miroslawa Nowak, Shuyan Du, et al.. (2023). Evaluation of BMS-986142, a reversible Bruton's tyrosine kinase inhibitor, for the treatment of rheumatoid arthritis: a phase 2, randomised, double-blind, dose-ranging, placebo-controlled, adaptive design study. The Lancet Rheumatology. 5(5). e263–e273. 6 indexed citations

Donnelly, David J., Joon‐Young Kim, Paul M. Scola, et al.. (2023). The discovery and evaluation of [18F]BMS-986229, a novel macrocyclic peptide PET radioligand for the measurement of PD-L1 expression and in-vivo PD-L1 target engagement. European Journal of Nuclear Medicine and Molecular Imaging. 51(4). 978–990. 13 indexed citations

Østergaard, Mikkel, Paul Bird, Chahin Pachaï, et al.. (2022). Implementation of the OMERACT Psoriatic Arthritis Magnetic Resonance Imaging Scoring System in a randomized phase IIb study of abatacept in psoriatic arthritis. Lara D. Veeken. 61(11). 4305–4313. 8 indexed citations

Decato, Benjamin E., Diana Julie Leeming, Jannie Marie Bülow Sand, et al.. (2022). LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis. Respiratory Research. 23(1). 61–61. 31 indexed citations

Chen, Li, Elizabeth Brown, Anne Minnich, et al.. (2022). Novel digital pathology quantitative image analysis and AI method detects the treatment effects of NASH drug candidates with a performance that benchmarks imaging-based measurements. Journal of Hepatology. 77. S446–S446. 2 indexed citations

10.

Abdelmalek, Manal F., Edgar D. Charles, Arun J. Sanyal, et al.. (2021). The FALCON program: Two phase 2b randomized, double-blind, placebo-controlled studies to assess the efficacy and safety of pegbelfermin in the treatment of patients with nonalcoholic steatohepatitis and bridging fibrosis or compensated cirrhosis. Contemporary Clinical Trials. 104. 106335–106335. 54 indexed citations

11.

Lawitz, Eric, Diane E. Shevell, Giridhar Tirucherai, et al.. (2021). BMS‐986263 in patients with advanced hepatic fibrosis: 36‐week results from a randomized, placebo‐controlled phase 2 trial. Hepatology. 75(4). 912–923. 71 indexed citations

12.

Dercle, Laurent, Matthew Fronheiser, Lin Lü, et al.. (2020). Identification of Non–Small Cell Lung Cancer Sensitive to Systemic Cancer Therapies Using Radiomics. Clinical Cancer Research. 26(9). 2151–2162. 128 indexed citations

13.

Smith, Ralph C., Joon‐Young Kim, David J. Donnelly, et al.. (2019). BMS-986327 as a novel PET imaging agent for assessment of LPA1 receptors in IPF. PA1399–PA1399. 1 indexed citations

14.

Leung, David, J. De Langen, David Raunig, et al.. (2018). Whole body PD-L1 PET in patients with NSCLC and melanoma.. Journal of Clinical Oncology. 36(5_suppl). 139–139. 2 indexed citations

15.

Martyanov, Viktor, Grace Hyun J. Kim, Wendy Hayes, et al.. (2017). Novel lung imaging biomarkers and skin gene expression subsetting in dasatinib treatment of systemic sclerosis-associated interstitial lung disease. PLoS ONE. 12(11). e0187580–e0187580. 58 indexed citations

16.

Gallezot, Jean‐Dominique, Nabeel Nabulsi, Daniel Holden, et al.. (2017). Evaluation of the Lysophosphatidic Acid Receptor Type 1 Radioligand ¹¹C-BMT-136088 for Lung Imaging in Rhesus Monkeys. Journal of Nuclear Medicine. 59(2). 327–333. 13 indexed citations

17.

Emami, Hamed, Esad Vucic, Sharath Subramanian, et al.. (2015). The effect of BMS-582949, a P38 mitogen-activated protein kinase (P38 MAPK) inhibitor on arterial inflammation: A multicenter FDG-PET trial. Atherosclerosis. 240(2). 490–496. 53 indexed citations

18.

Kivitz, A., Paulo Maciag, Parul Gulati, et al.. (2014). THU0109 Lack of Efficacy of CCR1 Antagonist BMS-817399 in Patients with Moderate to Severe Rheumatoid Arthritis: Results of 12-Week Proof-Of-Concept Study. Annals of the Rheumatic Diseases. 73. 215–215. 4 indexed citations

19.

Fan, Qiuling, et al.. (2011). Protein Expression Profile of Human Renal Mesangial Cells under High Glucose. American Journal of Nephrology. 34(1). 18–25. 7 indexed citations

20.

Du, Shuyan, et al.. (2005). Recovery of Metabolomic Spectral Sources using Non-negative Matrix Factorization. PubMed. 2005. 4731–4734. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact